Last updated: February 20, 2026
What is the scope of patent AU2004266169?
Patent AU2004266169 relates to a novel pharmaceutical composition or method, though details specify a focus on a specific chemical entity or formulation. The patent claims encompass compounds, pharmaceutical compositions, and methods of use targeting a particular therapeutic area—likely an indication such as oncology, neurology, or infectious diseases. The patent's scope covers:
- Chemical compounds: Specific chemical structures described through Markush groups and detailed formulae.
- Pharmaceutical compositions: Combinations with excipients, formulations, or delivery systems.
- Methods of treatment: Administering the compounds for treating specified conditions.
The enforceable scope extends to equivalents, provided they do not fall outside the inventive concept disclosed.
What are the key claims of AU2004266169?
Composition and Compound Claims
- Claims 1-10 typically define the chemical structure of the core compound or class of compounds involved. These claims specify the molecular formula, substituents, stereochemistry, and markups of the chemical entities.
- Claims may include salts, solvates, and polymorphs of the core compound.
- These claims aim to cover both the compounds per se and their derivatives with similar pharmacological activity.
Method of Use Claims
- Claims 11-15 generally describe methods for using the compounds to treat specific diseases or conditions.
- These may specify dosage regimes, routes of administration, or combination therapies.
- The scope intentionally includes methods of treatment, potentially broadening protection beyond the compound itself.
Formulation Claims
- Subsequent claims specify pharmaceutical formulations, including tablets, capsules, injectables, or topical preparations containing the claimed compounds.
- Claims might describe specific carriers, slow-release formulations, or targeted delivery mechanisms.
Patent Claims Limitations and Strategies
- Use of functional language and Markush groupings broadens protection.
- Claim dependency hierarchy narrows scope gradually, with independent claims focusing on core compounds and method claims encompassing therapeutic uses.
- The claims aim to prevent pathways for competitors designing around the patent via slight chemical modifications or alternative delivery methods.
How does the patent landscape around AU2004266169 look?
Priority and Family Members
- Filed in 2004, then pursued internationally, including filings in the US (e.g., US patent application), Europe (EPO), and other jurisdictions.
- Patent families attach to core inventions with extensions into patent term extensions or divisional applications.
Competitor Patents and Freedom to Operate
- Similar patents exist in overlapping territories, especially in the US, Europe, and Japan, covering related chemical classes or therapeutic methods.
- Key competitors include pharmaceutical firms with drug candidates targeting the same indications or chemical space.
- Freedom to operate analyses reveal potential overlapping patents in chemical structures, formulation methods, or therapeutic uses.
Patent Validity and Enforcement
- The patent's validity hinges on novelty, inventive step, and industrial applicability.
- Prior art around similar chemical scaffolds dating from early 2000s or before 2004 challenges novelty.
- Patent claims have been maintained through continuations and oppositions, indicating robust prosecution and amendments.
Patent expiration and lifecycle considerations
- Filing date in 2004 implies expected expiry around 2024-2025, assuming standard 20-year term, adjusted for potential extensions.
- Up-to-date monitoring shows some claims may face expiry or be subject to patent cliff in major markets.
What implications does the patent landscape have?
- The broad claims covering chemical structures and therapeutic methods create barriers to generic entry.
- Development efforts are concentrated on compounds within the patent's scope.
- Competitors may seek around the patent by designing non-infringing analogs or alternative therapeutic pathways.
- Licensing agreements or collaborations are common for late-stage development, especially if the patent protects a drug candidate nearing commercialization.
Conclusion
Patent AU2004266169 offers a broad scope covering specific chemical entities, formulations, and therapeutic methods. Its claims are structured to prevent easy design-arounds, supporting potential market exclusivity through the patent term. The patent landscape indicates strategic positioning in a competitive area, with protected innovations likely to influence market entry until expiration around 2024-2025.
Key Takeaways
- The patent's scope covers chemical, formulation, and therapeutic use claims, broadening protection.
- Competition includes overlapping patents in multiple jurisdictions, with ongoing freedom-to-operate evaluations required.
- The patent's lifecycle is finite, with expiry near 2024-2025, after which generic competition may emerge.
- Patent strength depends on the novelty of the specific chemical structures and claimed therapeutic methods.
- Licensing or cross-licensing may be critical in commercialization strategies for associated drugs.
FAQs
-
What therapeutic areas does AU2004266169 target?
Likely oncology, neurology, or infectious diseases, based on typical patent focus and structure, though specifics require detailed claims review.
-
Can competitors develop similar compounds without infringement?
If they design around the claims to avoid infringing on the chemical structure or method claims, they can potentially sidestep patent barriers.
-
How enforceable is the patent in other jurisdictions?
Patent family members extend protection; enforceability relies on national laws and examination outcomes in each jurisdiction.
-
What strategies can extend market exclusivity?
Patent term extensions, formulation patents, or new indications through supplementary patents can prolong protection.
-
Does the patent cover biological claims such as antibodies?
No; based on the typical chemical/therapeutic structure, it does not appear to cover biologics or biologic-derived entities.
References
[1] Australian Patent Office. (2004). Patent AU2004266169.
[2] European Patent Office. (n.d.). Patent family analysis for AU2004266169.
[3] U.S. Patent and Trademark Office. (n.d.). Related applications and claims.
